Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE46417 | ASTRAZENECA | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(1 year, 8 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6681768 | ASTRAZENECA | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(9 months ago) | |
US8051851 | ASTRAZENECA | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(3 years from now) | |
US10085974 | ASTRAZENECA | Dosage and formulation |
Mar, 2029
(5 years from now) | |
US11000517 | ASTRAZENECA | Dosage and formulation |
Mar, 2029
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Combination (NC) | Mar 29, 2022 |
Market Authorisation Date: 29 March, 2019
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)
Dosage: POWDER, METERED;INHALATION
8
United States
8
European Union
4
Spain
4
Denmark
4
Poland
4
Russia
4
Japan
4
Korea, Republic of
4
Portugal
4
Slovenia
3
RS
3
China
3
Croatia
3
Peru
3
Mexico
3
Hungary
2
Hong Kong
2
Brazil
2
Canada
2
Ukraine
2
New Zealand
2
Cyprus
2
Israel
2
Australia
2
Ecuador
2
South Africa
2
Lithuania
1
Uruguay
1
Austria
1
Malaysia
1
Germany
1
Singapore
1
Argentina
1
Norway
1
ME
1
Chile
1
Taiwan
1
Colombia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic